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Methods: In this study, we analyzed matched pairs of tumor specimens collected from 182 patients who received
neoadjuvant systemic therapies (NST). Statistical analyseswere conducted to determinewhether EGFR/HER2/RAS
pathway biomarkers and clinicopathological predictors, alone and in combination, are prognostic in breast cancer.
Findings: SIAH and EGFR outperform ER, PR, HER2 and Ki67 as two logical, sensitive and prognostic biomarkers in
metastatic breast cancer. We found that increased SIAH and EGFR expression correlated with advanced patholog-
ical stage and aggressive molecular subtypes. Both SIAH expression post-NST and NST-induced changes in EGFR
expression in invasive mammary tumors are associated with tumor regression and increased survival, whereas
ER, PR, and HER2were not. These results suggest that SIAH and EGFR are two prognostic biomarkers in breast can-
cer with lymph node metastases.
Interpretation: The discovery of incorporating tumor heterogeneity-independent and growth-sensitive RAS path-
way biomarkers, SIAH and EGFR, whose altered expression can be used to estimate therapeutic efﬁcacy, detect
emergence of resistant clones, forecast tumor regression, differentiate among partial responders, and predict pa-
tient survival in the neoadjuvant setting, has a clear clinical implication in personalizing breast cancer therapy.
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among women in the United States (Siegel et al., 2016). An estimated
231,840 patients were diagnosed with breast cancer and 40,450 of
them died of metastatic diseases in 2016 alone (Siegel et al., 2016;
DeSantis et al., 2014). Increased screening, improved mammary imag-
ing technologies, and targeted therapies have contributed to signiﬁcant
decreases in morbidity and mortality since the 1970s, and now more
than 90-percent of patients with early-stage breast cancer survive lon-
ger than ﬁve years (Graham et al., 2014; DeSantis et al., 2015). Despite
great scientiﬁc advancements and major clinical breakthroughs, pa-
tients diagnosed with invasive and malignant breast cancer still have a
poor prognosis (Penault-Llorca and Radosevic-Robin, 2016; Rakha et
al., 2008; Perou et al., 2000). The average survival for women diagnosed
withmetastatic disease is less than 2 years, despite aggressive therapies
such as surgery, radiation, and chemo-, immuno- and targeted therapies
(Grahamet al., 2014; Swain et al., 2015; Zardavas et al., 2013; Baselga et
al., 2012;Weigelt and Peterse, 2005). State-of-the-art treatmentmodal-
ities, such as anti-HER2 therapy, anti-ER therapy, anti-PI3K and anti-
mTOR therapy, tumor genome-guided combination therapies, stem
cell therapy, and anti-CTLA-4/PD1 immunotherapy, alone or in combi-
nation, are not curative in eradicating metastatic breast cancer (El
Saghir et al., 2011; McKeage and Perry, 2002; Romond et al., 2005;
Piccart-Gebhart et al., 2005; Robert et al., 2006; Engelman, 2009). This
is because invasive mammary tumors have tremendous inter- and
intra-tumor heterogeneity that becomesmore pronounced and diversi-
ﬁed inmetastatic diseases; therefore, effective therapies need to be per-
sonalized to shutdown the core tumor-driving pathways that promote
resistant tumor clonal expansion in breast cancer.
Neoadjuvant systemic therapies (NST), such as cytotoxic, endocrine,
targeted- and/or antibody-based agents, are routinely used to reduce
tumor burden and control aggressive tumor growth in locally advanced,
high-risk andmalignant subtypes (King andMorrow, 2015). An increas-
ing number of breast cancer patients with triple-negative breast cancer
(TNBC), HER2-positive, inﬂammatory, invasive or basal-like breast
cancer received NST prior to surgical resection (Arteaga et al., 2012;
King and Morrow, 2015; Thompson and Moulder-Thompson, 2012;
Nagayama et al., 2014). Preoperative NST provides a valuable window
of opportunity for in vivo monitoring of tumor responses in real time,
allowing evaluation of the antitumor therapeutic efﬁcacy of a given
therapy and, thus, offers invaluable prognostic information to predict
outcome and survival. Patients who had “complete” responses to NST,
with no residual tumor based on pathological analysis of breast tissues,
survived longer than patients who had incomplete responses (Morrow,
2016; Wang-Lopez et al., 2015; Cortazar et al., 2014; Parinyanitikul et
al., 2015; Petrarca et al., 2011). Therapy-induced tumor shrinkage mea-
sured by imaging technology in the clinicopathological settings can be
used to distinguish effective versus ineffective NST and identify “com-
plete” responders versus “non-responders” in clinical settings. Howev-
er, determining therapeutic efﬁcacy and quantifying tumor responses
to a given therapeuticmodality among “partial” responders—the largest
percentage of breast cancer patients—remains a major challenge
(Bulfoni et al., 2016; Falkson et al., 1992). Currently, there are no reliable
clinical biomarkers that can be used to consistently predict survival and
differentiate partial responders whose tumors regressed signiﬁcantly
versus the ones whose resistant tumor clones started emerging after
tumor debulking post-NST.
In addition to imaging-guided technology tomonitor the therapy ef-
ﬁcacy, sensitive and reliable biomarker panels should be developed in
the neoadjuvant setting to select, quantify, and optimize ﬁrst-line ther-
apies to treat locally advanced breast cancer. Breast tumor biomarkers
such as ER, PR, and HER2 do not correlate with tumor response nor do
they predict patient survival in high-grade, therapy-resistant, invasive
and metastatic diseases (Tevaarwerk et al., 2013; Gown, 2008; Chen et
al., 2012; Onitilo et al., 2009; Joensuu et al., 2013; Parise and Caggiano,2014; Prat et al., 2015). Importantly, the clinical reality is that there is
little to no ﬂexibility in changing standard therapy once it is started.
As a result, most patients with malignant tumors, especially those
who only “partially” respond to a given therapy, have to endure the tox-
icities of the full regimens, often waiting months or years for tumor re-
lapse, progressive diseases, and systematic metastasis before knowing
whether the prescribed regimens were effective in eradicating their tu-
mors. Patients who receive ineffective ﬁrst-line therapies or experience
therapy-induced resistant tumor clonal expansion will miss an impor-
tant window if no effective follow-up therapy is added in a timely fash-
ion to remedy the inadequacy. A majority of breast cancer patients fall
under this category of “partial responders” and face uncertain futures.
There is a pressing need to identify reliable and robust prognostic bio-
markers to closely monitor tumor regression in real time, and impor-
tantly, to determine whether ﬁrst-line therapies prescribed are
effective against high-risk and invasive mammary tumors.
Although oncogenic K-RAS mutations are rare in mammary tumors
(observed in about 5-percent of patients), genomic studies have indicat-
ed that the EGFR/HER2/K-RAS “pathway” is activated in a large propor-
tion of aggressive and malignant breast cancers (Arteaga et al., 2012;
Foulkes et al., 2010). EGFR/HER2/K-RAS activation has been correlated
with shortened survival, resistance to therapy, and tumor relapse de-
spite aggressive treatments in breast cancer (Tebbutt et al., 2013;
Wright et al., 2015). As a major tumor-promoting signaling pathway,
we investigated whether EGFR/HER2/RAS pathway biomarker expres-
sion can be added to evaluate therapy efﬁcacy and predict patient sur-
vival in breast cancer. In this study, we report that activation or
inactivation of the tumor-promoting RAS pathway biomarkers, SIAH
and EGFR, is associated with tumor progression versus regression in
mammary tumors post-NST. We ﬁnd that NST-induced reduction of
SIAH and EGFR expression can be used as surrogate prognostic bio-
markers to quantify therapeutic efﬁcacy, determine tumor responses,
detect emerging resistant clones, and predict survival in invasive breast
cancer, regardless of tumor heterogeneity, in the neoadjuvant setting.
2. Materials and Methods
2.1. Ethical Statement
With the proper approval by two Institutional Review Boards (IRB)
at Eastern Virginia Medical School and Sentara Hospital Systems, this
clinical study was conducted in full compliance of HIPAA regulations
to protect patient privacy and conﬁdentiality.
2.2. Patient Selection
This research project was designed and executed as per REMARK
and RECIST criteria for tumor biomarker studies (McShane et al., 2005;
Altman et al., 2012; Eisenhauer et al., 2009). This retrospective study
was conducted using data from breast tumor tissue collected from all
patients diagnosed with invasive and high-risk carcinoma of the breast
between August 2007 and December 2010. A cohort of 182womenwas
identiﬁed who received NST treatment, and then surgical resection
under the care of Sentara Hospital Systems. Clinicopathological and
treatment course data were extracted and de-identiﬁed following ex-
tensive chart review of patients’ electronic medical records in Sentara’s
EPIC database (Table 1). All patients received standard NST regimens
as prescribed by their oncologists following NCI guidelines (Supple-
mental Table S1). Patients typically received a combination of
chemotherapies (anthracyclines, alkylating agents, taxanes, and/or
metabolic inhibitors), plus hormone and/or anti-HER2 therapies in
conjunction. Post-NST, all patients underwent surgical resections,
performed by 24 local surgical oncologists, to excise their primary
tumors (either total mastectomy, radical mastectomy, modiﬁed
radical mastectomy, segmental mastectomy, or lumpectomy)
(Supplemental Table S1).
Table 1
Descriptive statistics of clinicopathological variables and molecular biomarker expression in this breast cancer patient cohort.
Variables Level Median or Frequency IQR or % p-Value1
A. Patient demographics
Age (year) at diagnosis 54.0 (27–88) 17.8 0.00584
Body mass index (kg/m2) at diagnosis 29.4 (16.8–60.6) 9.0 0.608
Stage at diagnosis 2.27 × 10−8
Stage I 22 12.1%
Stage II 101 55.5%
Stage III 46 25.3%
Stage IV 13 7.1%
Tumor size at diagnosis 5.88 × 10−10
T1: ≤2-cm 39 21.4%
T2: N2-cm to ≤5-cm 95 52.2%
T3: N5-cm 29 16.0%
T4: Inﬂammatory BC; chest wall inﬁltration 19 10.4%
Tumor grade 0.169
I 30 16.5%
II 45 24.7%
III 96 52.8%
Not determined 11 6.0%
Tumor histology 0.813
Ductal 159 87.4%
Lobular 12 6.6%
Ductal + lobular 10 5.5%
Mucinous 1 0.5%
Lymph node status at
diagnosis
1.66 × 10−7
Negative 79 43.4%
Positive 103 56.6%
Molecular subtype 0.0159
Luminal A 91 50.0%
Luminal B 20 11.0%
HER2-type 18 9.9%
Triple negative 53 29.1%
B. Receptor status
Variables Level Frequency % p-Value1
Estrogen receptor (ER) status 0.007
Negative 77 42.3%
Positive 105 57.7%
Progesterone receptor (PR) status 0.0237
Negative 88 48.4%
Positive 94 51.6%
HER2 status 0.644
Negative 144 79.1%
Positive 38 20.9%
C. Treatment information
Variables Level Frequency % p-Value1
Neoadjuvant treatment
Chemotherapy Received 153 84.1% 0.245
Did not receive 29 15.9%
Hormone therapy Received 26 14.3% 0.768
Did not receive 156 85.7%
Antibody therapy Received 32 17.6% 0.652
Did not receive 150 82.4%
Pathological response after NAT 0.0179
Complete response (pCR) No residual tumor 33 18.1%
Incomplete response (pIR) Partial response 117 64.3%
No response 15 8.2%
Unknown 17 9.4%
Adjuvant treatment
Chemotherapy Received 34 18.7% 5.64 × 10−6
Did not receive 148 81.3%
Hormone therapy Received 94 51.6% 0.00692
Did not receive 88 48.4%
Antibody therapy Received 32 17.6% 0.670
Did not receive 150 82.4%
Radiation therapy (XRT) Received 134 73.6% 0.620
Did not receive 48 26.4%
D. RAS pathway biomarkers
Variables Level Median or
frequency
IQR or % p-Value1
SIAH
pre-NAT (needle biopsy) Median expression, % 40.0 (1.0–97.0) 55.0
Low ≤ 30% 83 45.6% 0.0463
High N 30% 95 52.2%
Not available 4 2.2%
(continued on next page)
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Table 1 (continued)
Variables Level Median or Frequency IQR or % p-Value1
post-NAT (s/p resection) Median expression, % 3.0 (0.0–92.0) 20.0
Low ≤ 30% 150 82.4% 0.00188
High N 30% 30 16.5%
Not available 2 1.1%
NAT-induced change High N 30%➔ Low ≤30% 67 36.8% 0.00144
High N 30%➔ High N 30% 27 14.8%
Low ≤ 30%➔ Low ≤ 30% 81 44.5%
Not available 7 3.9%
EGFR
pre-NAT (needle biopsy) Median expression, % 0 (0-3+) 1+
Low ≤+ 1 131 72.0% 0.00107
High N+ 1 48 26.4%
Not available 3 1.6%
post-NAT (s/p resection) Median expression, % 0 (0-3+) 1+
Low ≤+1 158 86.8% 0.00513
High N+1 23 12.6%
Not available 1 0.6%
NAT-induced change High N+1➔ Low ≤+ 1 28 15.4% 0.00146
High N+ 1➔ High N+1 19 10.4%
Low ≤+ 1➔ Low ≤+ 1 127 69.8%
Not available 8 4.4%
phospho-ERK
pre-NAT Median expression, % 10.0 (0.0–95.0) 27.5
Low b 1 39 21.4% 0.429
High ≥ 1 138 75.8%
Not available 5 2.8%
post-NAT Median expression, % 0.0 (0.0–95.0) 0.0
Low b 1 150 82.4% 0.141
High ≥ 1 29 15.9%
Not available 3 1.7%
NAT-induced change High ≥ 1➔ Low b 1 113 62.1% 0.336
High ≥ 1➔ High 24 13.2%
Low b 1➔ Low b 1 35 19.2%
Not available 10 5.5%
Ki67
pre-NAT Median expression, % 11.3 (0.0–92.5) 21.9
Low ≤ 10% 89 48.9% 0.764
High N 10% 89 48.9%
Not available 4 2.2%
post-NAT Median expression, % 1.0 (0.0–94.5) 5.5
Low ≤ 10% 151 83.0% 0.390
High N 10% 30 16.5%
Not available 1 0.5%
NAT-induced change High N 10%➔ Low ≤ 10% 63 34.6% 0.601
High N 10%➔ High N 10% 25 13.7%
Low ≤ 10%➔ Low ≤ 10% 86 47.3%
Not available 8 4.4%
E. Clinical outcomes of overall survival and vital status
Variables Level Median or frequency IQR or %
Length of disease (days since diagnosis) 1610 622
(230-2438)
Vital status at last follow-up
Alive 149 81.9%
without distant metastasis 134 73.6%
with distant metastasis 15 8.3%
Dead 33 18.1%
without distant metastasis 3 1.6%
with distant metastasis 30 16.5%
1 Log-rank test for categorical variables and Cox proportional hazards model (or Wilcoxen two-sample t-test) for continuous variable.
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aspiration biopsy of the primary breast tumor that led to the initial diag-
nosis. The only selection criteria were the availability of the matched
pre- and post-NST tumor biospecimens. Study endpoints were deter-
mined either by the date of patient death, or the last documented fol-
low-up examination at time of chart review. Data on tumor stage at
diagnosis (pathological and clinical), treatment courses including neo-
adjuvant and adjuvant therapies (chemotherapy, hormone therapy,
and/or antibody therapy), patient outcome (cancer remission, metasta-
sis, or recurrence), and vital statuswere obtained per reviewof patients’records (see Table 1 and Supplemental Table S1). Datawere collected on
tumor histological type, size, pathological grade, hormone receptor (ER
and PR) or HER2 expression, lymph node status, and response to NST
from pathology reports in EPIC.
2.3. Pathology Samples
Following the dual IRB approval at EVMS and Sentara, we collected
tumor samples and clinical data from a total of 182 patients with prima-
ry operable breast tumors, including 364 parafﬁn-embedded tumor
187L.L.S. van Reesema et al. / EBioMedicine 11 (2016) 183–198blocks of invasive carcinoma collected pre- and post-NST from eight
Sentara hospitals: Sentara Careplex Hospital (Hampton, VA), Sentara
Leigh Hospital (Norfolk, VA), Sentara Norfolk General Hospital (Norfolk,
VA), Sentara ObiciHospital (Suffolk, VA), Sentara PortWarwickHospital
(Newport News, VA), Sentara Princess Anne Hospital (Virginia Beach,
VA), Sentara Virginia Beach General Hospital (Virginia Beach, VA), and
Sentara Williamsburg Regional Medical Center (Williamsburg, VA).
Histology and pathology analyses were performed by two board-
certiﬁed clinical pathologists, JSW and CFO. Pathology and immunohis-
tochemistry protocols have been optimized to detect the ER, PR, HER2,
EGFR, phosphorylated ERK (phospho-ERK), Ki67, and SIAH expression
from the matched pairs of tumor blocks pre- and post-NST. All staining
and pathological analyses were conducted at the Pathology Sciences
Medical Group and Sentara Norfolk General Hospital’s Pathology Unit
under the supervision of J.S. Winston, M.D., a breast disease expert
and clinical pathologist who identiﬁed representative tumor parafﬁn
blocks, coordinated and guided the pathological study, controlled the
quality of the IHC staining, and scored the slides independently along
with C.F. O’Connor in a double blind fashion. The diagnostic tumor nee-
dle biopsy pre-NST and surgically resected tumor tissues post-NSTwere
selected for serial immunohistochemistry (IHC) staining and clinico-
pathological studies.
2.4. Immunohistochemistry
Four-micrometer tissue sections were cut from tumor parafﬁn
blocks and slides were stained using Ventana Benchmark Ultra,
according to the manufacturer’s protocol. The IHC experiments
were carried out using monoclonal anti-EGFR (Ventana clone 5B7,
pre-diluted, Ventana Medical Systems Cat# 790-4347, Roche, USA,
RRID:AB_2617183), monoclonal anti-phospho-ERK (1:750 dilution,
Cell Signaling, Danvers, MA, RRID:AB_331646), monoclonal anti-SIAH
24E6H3 (1:40 dilution, Novus, CA, RRID:AB_1217916), monoclonal
anti-Ki67 (1:100 dilution, Dako, Denmark, RRID:AB_2142367),
monoclonal anti-ER (Ventana clone SP1, pre-diluted, Roche, USA,
RRID:AB_2335977), monoclonal anti-PR (Ventana clone 1E2, pre-
diluted, Roche, USA, RRID:AB_2335976), and monoclonal anti-HER2
(Ventana clone 4B5, pre-diluted, Roche, USA, RRID:AB_2335975) anti-
bodies. The IHCwas performed on a BenchMark ULTRA fully automated
IHC/ISH staining instrument (Ventana Medical Systems, Inc., Tucson,
AZ).
2.5. Tumor Block Review and the Immunohistochemical Quantiﬁcation
Original hematoxylin and eosin (H&E) and immunohistochemistry
(IHC) slides used for clinical diagnosis collected pre- and post-NST for
each patient (1-3 slides per patient) were independently reviewed
and scored in a double blind manner by JSW and CFO. Slides stained
for ER, PR, Ki67, or SIAH, were scored using the percentage of positive
IHC stainingwithin the tumor. Slideswith a score discrepancy of greater
than 10-percent were then dually re-evaluated by two pathologists to-
gether to reach a ﬁnal consensus score. Slides stained for HER2 or EGFR
were scored as 0 (nomembrane staining), 1+ (partialmembrane stain-
ing), 2+ (complete membrane staining in less than 30% of the tumor
cells), or 3+ (complete membrane staining in more than 30% of the
tumor cells). Slides stained for phospho-ERK were scored as the per-
centage of tumor cells with cytoplasmic staining. All histology images
presented were captured at 400-fold magniﬁcation using a Leica com-
pound microscope and Leica DC500 digital camera.
2.6. Statistical Analyses
Overall survival times ranged from230days (0.6 years) to 2438days
(6.7 years), with amedian survival of 1610 days (4.4 years). For patients
initially diagnosed without distant metastasis, time of distant recur-
rence-free survival was calculated either as the number of days fromthe date of initial diagnosis until the date of ﬁrst documentedmetastasis
per imaging studies, or censored at the date of last documented follow-
up evaluation listed in the EPIC database (as of August 31, 2014).
To describe the data, medians and interquartile ranges (IQR) were
used for continuous variables while frequencies and percentages were
used for categorical variables. Spearman’s correlation coefﬁcients were
calculated to evaluate correlations among clinicopathological and mo-
lecular biomarker variables (Table 2). The Kaplan-Meier method was
used for all survival curve analyses. In univariate analysis, the log-rank
test was used to calculate the difference in survival for categorical vari-
ables. The Cox proportional hazardsmodel was used for continuous var-
iables; thismodelwas also used formultivariate survival analyses of the
association of survival with patient age, tumor size, molecular subtypes,
stage, presence of lymph nodemetastasis, and the level of ER, PR, HER2,
phospho-ERK, Ki67, SIAH, or EGFR (Table 3). The proportional hazards
model assumptions were veriﬁed using the log-transformation plot;
goodness-of-ﬁt of themodelswere checked bymartingale and deviance
residual plots. The time-dependent receiver operating characteristic
(survival ROC) was applied to display and compare the sensitivity and
speciﬁcity of the predictive models based on the multivariate survival
analysis (Heagerty and Zheng, 2005). The survival ROC curves were
used to accommodate the time-dependent nature and censoring in
the survival data. All P-values calculated were two-sided. A P-value of
less than 0.05 was considered statistically signiﬁcant. Statistical plots
were generated using R software Version 3.2.1 (R Core Team, 2015).3. Results
3.1. Increased Expression of SIAH and EGFR, Two RAS Pathway Biomarkers,
are Correlated With Advanced Tumor Grade and Aggressive Molecular
Subtypes
It is challenging to predict accurately which individual breast cancer
patients will beneﬁt from standard therapies and which ones will not,
based on the existing biomarker panels and advanced imaging technol-
ogy. Consistent with the published literature, the increased pathological
stage and aggressive molecular subtypes were correlated with poor
clinical outcome and reduced patient survival (Fig. 1A and B), while in-
creased tumor grades were not associated with survival at 7-years (Fig.
1C). To demonstrate the prognostic values of the tumor-driving RAS
pathway biomarkers in high-risk breast cancer patients, we compared
altered expression levels of 4 biomarkers in the RAS pathway in the
paired tumor biospecimens collected in pre- and post-NST (Fig. 1D).
That includes two upstream receptors (HER2 and EGFR), a mid-stream
kinase (phospho-ERK) and the most downstream E3 ligase (SIAH) in
paired tumor biospecimens collected from 182 breast cancer patients
who received NST at Sentara Hospitals. The 4 mammary tumor bio-
markers, HER2, ER, PR and Ki67, were utilized as internal controls for
this study. Among all the 182 treatment-naive needle biopsy tumor
biospecimens, SIAH expression was detected in 97.8% of all the SIAH
IHC slides – 52.2% of them displayed a high SIAH expression level that
markedmore than 30% of tumor cells, whereas 45.6% of them displayed
a lowSIAH expression thatmarked equal or less than 30% of tumor cells;
Similarly, EGFR expression was detected in 26.4% of all the EGFR IHC
slides, with an EGFR score thatwas higher than 1; and phospho-ERK ex-
pressionwas detected in 75.8% of the phospho-ERK IHC slides (Table 1).
As controls, HER2 was detected in 20.9% of treatment-naïve tumor
biospecimens, ER in 57.7% and PR in 51.6% (Table 1). SIAH expression
was associated with active tumor cell proliferation, and it was robust,
tumor-speciﬁc, and therapy-responsive (Fig. 1 and Supplemental Fig.
S1). Mean levels of SIAH, EGFR, and Ki67 increased with tumor grade
and aggressive molecular subtypes at treatment-naïve tumors (Fig. 1E
andG). Increased tumor grade and aggressivemolecular subtype exhib-
ited a much higher level of endogenous SIAH or EGFR expression pre-
and post-NST in breast cancer (Fig. 1F and H).
Table 2
Spearman's correlation coefﬁcients between clinical variables, ER, PR, HER2 and RAS pathway biomarkers.
Clinical variables or
Biomarkers
Stage Tumor Size Tumor grade Lymph node status Molecular subtype ER PR HER2 pre-NAT post-NAT Relative
change
SIAH EGFR SIAH EGFR SIAH EGFR
Stage 1
Tumor size 0.66 1
Tumor grade 1
Lymph node status 0.53 0.38 1
Molecular subtype 0.50 1
ER 0.91 1
PR -0.48 0.79 0.75 1
HER2 1
pre-NAT SIAH 0.48 0.45 −0.47 -0.41 1
EGFR 0.31 0.32 −0.37 -0.34 0.35 1
post-NAT SIAH 0.49 0.47 −0.53 -0.43 0.80 0.71 1
EGFR 0.47 0.50 −0.57 -0.47 0.51 0.37 0.53 1
Relative change SIAH 0.32 0.30 −0.36 -0.31 0.35 0.55 0.52 0.57 1
EGFR 0.43 0.36 −0.44 -0.36 0.48 0.42 0.79 0.54 1
Note: Only correlations that are statistically signiﬁcant (p ≤ 0.05), with coefﬁcients greater than |0.30| are shown.
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ed With Tumor Regression, as Reﬂected in the NST Efﬁcacy and Increased
Patient Survival
We hypothesized that effective NST, which has been shown to slow
tumor growth and reduce tumor volume, would inactivate or decrease
the RAS pathway signal that drives mammary tumor progression and
metastasis. Ineffective therapy would therefore neither impede the ac-
tive RAS pathway signal nor inhibit tumor growth. Importantly, thera-
py-resistant tumor clones can be easily identiﬁed by SIAH-positive
staining in the surgically resected tumors post-NST. Thus, loss of and/
or decrease in SIAH expression, which reﬂects the inactivation of this
tumor-promoting RAS pathway, may serve as a reliable indicator of an
effective NST modality. In contrast, persistent SIAH expression,
reﬂecting RAS pathway activation, may serve as a reliable predictor of
an ineffective NST modality and a sensitive readout of emerging resis-
tant clones in invasive breast cancer.
Compared to the mean expression levels of SIAH, EGFR, and Ki67 in
treatment-naïve tumors (Fig. 1E and G), SIAH, EGFR, and Ki67 expres-
sion decreased signiﬁcantly in a majority of resected tumors post-NST,
suggesting that current standard NST is effective in suppressing mam-
mary tumor growth (Fig. 1F and H). The pattern of the mean level of
SIAH, EGFR and Ki67 expression remained similar and statistically sig-
niﬁcant pre- and post-NST, correlatedwith grades, stages andmolecular
subtypes (Fig. 1E–H). In contrast, mean levels of phospho-ERK expres-
sion decreased with increased tumor grades (Fig. 1E). The NST-induced
loss of SIAH expression could be used to identify super-responders and
partial responders with good outcome and best survival (Fig. 1I and
Supplemental Fig. S1A, S1C and S1E), whereas the persistent high
SIAH expression post NST seemed to identify non-responders and par-
tial responders with poor outcome and reduced survival (Fig. 1J and
Supplemental Fig. S1B, S1D and S1F).3.3. The Prognostic Value of SIAH and EGFR Expression in Breast Cancer Pre-
and Post-NST
To determinewhether the therapy-induced reduction in SIAH, EGFR
and Ki67 pre- and post-NST have added prognostic values in breast can-
cer, we conducted statistical analyses to examine the clinical outcomeof
the breast cancer patients whose tumors retained high SIAH/EGFR/Ki67
expression post-NST, versus that of the patients whose tumors lost
SIAH/EGFR/Ki67 expression completely or partially post-NST when
compared to their treatment-naïve tumors. We segregated treatment-
naïve tumors (182 of them) into two roughly equal groups: “high”
SIAH expression (N30% positive tumor cells) and “low” SIAH expression(≤30% positive tumor cells). At the time of diagnosis prior to NST, about
50% patients had tumors with high SIAH expression and another 50%
patients had low SIAH expression (Table 1). The same criteria of high
(N30%) or low (≤30%) SIAH expression was applied to the surgically
resected tumors post-NST. Following clinical classiﬁcation, high EGFR
expression is deﬁned as N1+ (score of 2+ or 3+); while negative or
low EGFR expression is deﬁned as ≤1+ (score of 1+ or 0) in tumor
cells. About 50% patients had tumors with high Ki67 expression (N10%
positive tumor cells) and another 50% patients had low Ki67 expression
(≤10% positive tumor cells) pre-NST. The same criteria of high (N10%)
or low (≤10%) Ki67 biomarker expression was applied to the surgically
resected mammary tumors post-NST (Table 1).
By performing the univariate analysis over a 7-year period, we found
that ER, PR, SIAH, and EGFR expression was statistically associated with
survival (log-rank P b 0.05) (Fig. 2). The ER and PR positivity in luminal
breast tumors was a biomarker of extended survival (Fig. 2A and B). In
contrast, the level of HER2, phospho-ERK or Ki67 expressionwas not as-
sociated with tumor response or patient survival (Fig. 2C and data not
shown). Activation of the EGFR/SIAH pathway is indicative of tumor
progression, while its inactivation is indicative of mammary tumor re-
gression post-NST. Hence, low levels of SIAH and/or EGFR expression
post-NST correlated with tumor regression and increased survival,
whereas high levels of SIAH and/or EGFR expression in tumor
biospecimens pre- and post-NST were associated with progressive dis-
eases, therapy-induced resistance, metastasis to sentinel lymph node
and beyond, and decreased survival (Figs. 1 and 2). Univariate analysis
showed that the endogenous SIAH/EGFR expression in mammary tu-
mors pre- and post-NST, and therapy-induced reduction in SIAH or
EGFR expression post-NST, were prognostic of patient survival (Fig.
2D–I).
3.4. The Prognostic Value of SIAH and EGFR in Metastatic Breast Cancer
Univariate analyses showed an added prognostic value of SIAH and
EGFR, to predict tumor response, therapy efﬁcacy and patient survival
in breast cancer (Fig. 2). Clinically, the detection of sentinel lymph
node (LN) metastases at diagnosis is clearly associated with a reduced
survival in breast cancer (Penault-Llorca and Radosevic-Robin, 2016;
Jatoi et al., 1999; Weigelt and Peterse, 2005; Ozmen et al., 2015;
Gipponi et al., 2004; Rakha et al., 2012). Cancer-related deaths occurred
only in patients whose tumors had spread to the sentinel lymph nodes
(LN) and beyond. Increased SIAH, EGFR and Ki67 expression were de-
tected in metastatic breast cancer, including malignant tumors that
had invaded sentinel LN, and/ormetastasized to distant organs, as com-
pared to mammary tumors with no detectable LN metastases (Figs. 1
and 3, and Table 1). Here, our survival analyses were further stratiﬁed
Table 3
Cox proportional hazards regression models with clinical variables and RAS pathway
biomarkers
Predictors Level Hazard
ratio
95% Conﬁdence
interval
p-Value
Lower
bound
Upper
bound
A. Pre-neoadjuvant therapy
Age – 1.0409 1.0079 1.0749 0.01459*
Molecular
subtype
Luminal A 0.2437 0.09739 0.6097 0.002549**
Luminal B
HER-2 type
TNBC
Histology Ductal 2.1953 1.0874 4.4318 0.02825*
Lobular
Mixed
Tumor size T1 2.1612 1.3838 3.3754 0.0007050***
T2
T3
T4
ER Negative 15.0042 1.4257 157.9058 0.02411*
Positive
pre-Ki67 Low ≤ 10% 0.3518 0.1497 0.8267 0.01655*
High N 10%
pre-SIAH Low ≤ 30% 1.2926 0.5117 3.2652 0.5872
High N 30%
pre-EGFR Low ≤+ 1 2.1204 0.8789 5.1150 0.09435
High N+ 1
B. Post-neoadjuvant therapy
Age – 1.0283 0.9951 1.0636 0.09590
Molecular
subtype
Luminal A 0.3467 0.1412 0.8513 0.0208*
Luminal B
HER-2 type
TNBC
Histology Ductal 2.6777 1.2805 5.5994 0.008876**
Lobular
Mixed
Tumor size T1 2.07757 1.3575 3.1795 0.000758***
T2
T3
T4
ER Negative 7.8666 0.7989 77.4615 0.07714
Positive
post-Ki67 Low ≤ 10% 0.2680 0.07119 1.0087 0.05152
High N 10%
post-SIAH Low ≤ 30% 4.4579 1.3383 14.8494 0.01491*
High N 30%
post-EGFR Low ≤+1 2.4207 0.8759 6.6906 0.088304
High N+1
C. Relative change after neoadjuvant therapy
Age – 1.0532 1.0176 1.0901 0.00316**
Molecular
subtype
Luminal A 0.2199 0.08659 0.5586 0.00145**
Luminal B
HER-2 type
TNBC
Histology Ductal 2.3088 1.1511 4.6308 0.01846*
Lobular
Mixed
Tumor size T1 1.8953 1.2286 2.9239 0.00384**
T2
T3
T4
ER Negative 24.2180 2.1442 273.5388 0.00998**
Positive
ΔKi67 Low➔ Low 0.4504 0.2086 0.9728 0.04234*
High➔ Low
High➔ High
ΔSIAH Low➔ Low 1.8881 0.8338 4.2757 0.1275
High➔ Low
High➔ High
ΔEGFR Low➔ Low 2.5837 1.3507 4.9426 0.00413**
High➔ Low
High➔ High
* P b 0.05
** P b 0.01
*** P b 0.001
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duration of this study, and thus their 5–7 years survivals are indepen-
dent of tumor grades, pathological stages, molecular subtypes, and bio-
marker expression (Fig. 4). Importantly, we found that SIAH and EGFR
have additional prognostic values to predict patient survival inmetasta-
tic breast cancer (Figs. 3 and 4).
Among patients with LNmetastases, the therapy-induced reduction
in SIAH expression seemed to correlate with increased survival; i.e., the
patients with low SIAH expression in both pre- and post-NST settings
have the best prognosis and the greatest survival beneﬁt despite their
invasion phenotypes, whereas patients with high SIAH expression in
both pre- and post-NST settings have the worst prognosis, suggesting
that either ineffective therapywas administered or therapy-induced re-
sistant tumor clones were emerging (Figs. 3A, C–F, 4A, B and C). The pa-
tients with high SIAH expression at diagnosis and low SIAH expression
post-NST have intermediate survival, suggesting that an effective NST
modality was administered to inhibit tumorigenesis (Figs. 3A, 4A, B
and C). Amongpatientswith LNmetastases, the therapy-induced reduc-
tion in EGFR expression is statistically signiﬁcant to correlate with in-
creased survival (Figs. 3B, C–F, 4D, E and F). Patients with low EGFR
expression in both pre- and post-NST settings have the best prognosis
despite their invasive phenotypes and LN positivity, whereas patients
with high EGFR expression in both pre- and post-NST settings have
theworst prognosis, and patients with high EGFR expression at diagno-
sis and low EGFR expression post-NST have intermediate survival (Figs.
3B, 4D, E and F). In the cases of persistent high EGFR expression post-
NST, additional anti-EGFR therapy should be added to control these
therapy-refractory and EGFR-positive mammary tumors that have
metastasized.
3.5. Multivariate Survival Analysis
To demonstrate the clinical prognostic values of SIAH and EGFR in
breast cancer, we performed multivariate analyses of 7 molecular bio-
markers (SIAH, EGFR, phospho-ERK, ER, PR, HER2 and Ki67) and com-
pared them to 4 clinicopathological predictors (pathological stages,
molecular subtypes, tumor size and LN positivity). ER, PR, HER2 and
Ki67 were used as biomarker controls. Variables that were signiﬁcantly
associated (P b 0.05) with patient survival included molecular subtype,
histology, tumor size, Ki67 expression at diagnosis, SIAH expression
post-NST, and a NST-induced reduction in EGFR and Ki67 expression
in patients with metastatic diseases (Fig. 3, Table 2 and Table 3). Older
age pre-NST and high SIAH expression in tumors post-NST were signif-
icantly associated with reduced survival (Table 3). Survival curves,
stratiﬁed by LN status, showed that a signiﬁcantly smaller proportion
of patients whose invasive tumors had high levels of SIAH and EGFR
pre- and post-NST survived for 7 years post-NST, compared to patients
whose invasive tumors had low levels of SIAH and EGFR expression
pre- and post-NST (Fig. 4 and Table 3).
Multivariate time-dependent survival receiver operating character-
istic (survival ROC) and area under the curve (AUC) plots were generat-
ed to determine the ability of various combinations of 7 molecular
biomarkers and 4 clinicopathological predictors to predict patient sur-
vival (Fig. 5). Of all biomarker combinations analyzed, SIAH, EGFR and
SIAH/EGFR combination had the highest AUC and ROC values in
predicting patient survival (Fig. 5A, B and C, and Fig. 5G, H and I). Nota-
bly, these two RAS pathway biomarkers alone have demonstrated an
impressive prognostic power that is comparable to that of the clinical
gold standards, i.e., LNmetastases and/or 4 clinical predictors in combi-
nation (Fig. 5D, E, and F, and Fig. 5J, K and L). The prognostic values of
SIAH and EGFR are far superior to that of Ki67, and/or ER, PR, and
HER2 — the universally used biomarker standards in breast cancer
clinics (Fig. 5A, B and C, and Fig. 5J, K and L). The ROC and AUC analyses
demonstrated that clinicopathological predictors are still a reliable pre-
dictor of patient survival at 5–7 years, and we discovered that SIAH and
EGFR are highly prognostic in breast cancer (Fig. 5). It is important to
Fig. 1. TwoRASpathway biomarkers, SIAH and EGFR,whose expression in breast cancer correlatedwith increased tumor grades and aggressivemolecular subtypes pre- and post-NST. (A)
Pathological stages are statistically associated with patient survival with P value of 2.27 × 10−8. (B) Molecular subtypes are statistically associated with patient survival with P value of
0.016. (C) Tumor grade are not associated with patient survival. (D) A schematic illustration of the EGFR/HER2/RAS signaling pathway is shown. The expression of the two upstream
receptors, EGFR/HER2, the midstream kinases, phospho-ERK, and the most downstream signaling gatekeeper, SIAH E3 ligase, were examined. (E–F) Levels of SIAH, EGFR, and Ki67
expression in breast cancer increased with tumor grades, pre- and post-NST. NST signiﬁcantly reduced levels of EGFR, SIAH, phospho-ERK, and Ki67. (G–H) Levels of SIAH, EGFR, and
Ki67 expression increased in aggressive molecular subtypes of mammary tumors, pre- and post-NST. Levels of phospho-ERK expression were not correlated with molecular subtypes.
NST signiﬁcantly reduced levels of EGFR, SIAH, phospho-ERK, and Ki67, in a majority of resected primary mammary tumors. (I–J) Radiographic (MRI) images of human breasts and
breast cancer pre- and post-NST were shown. Treatment-naïve tumor cells in high-grade and high-risk mammary tumors expressed high SIAH. (I) Fewer tumor cells expressed high
SIAH post-NST. Based on diminished SIAH expression, we categorized patients as super-responders, whose tumor regressed completely post-NST. Three patients had dramatic
reductions in SIAH expression (marked by blue arrows); more than 95% of tumor cells expressed SIAH pre-NST, compared with less than 1% tumor cells expressed SIAH post-NST.
These patients had no evidence of tumor recurrence 7 years post-NST. (J) Three patients whose tumors had a high SIAH expression post-NST (marked by red arrows) were categorized
as non-responders, whose tumors regress less than 20-30% post-NST, and who had shortened survival time due to progressive diseases and LN metastases.
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Fig. 2.Kaplan-Meier survival curves of SIAH and EGFR expression in univariate analyses. (A) Tumor expression of ER is associatedwith increased patient survivalwith P value of 0.007. (B)
Tumor expression of PR is associated with increased patient survival with P value of 0.024. (C) Tumor expression of HER2 is not associated with patient survival. (D) Tumor expression of
high SIAH expression (N30% of tumor cells expressing SIAH) pre-NST is associatedwith decreased patient survival with P value of 0.046. (E) Tumor expression of high SIAH level (b30% of
tumor cells expressing SIAH) post-NST is associated with decreased patient survival with P value of 0.002. (F) Therapy-induced reduction in SIAH expression post-NST is associated with
increased patient survival with P value of 0.001. (G) Tumor expression of high EGFR level (N1) pre-NST is associated with decreased patient survival with P value of 0.001. (H) Tumor
expression of high EGFR level (N1) post-NST is associated with decreased patient survival with P value of 0.005. (I) Therapy-induced reduction in EGFR expression post-NST is
associated with increased survival time with P value of 0.001.
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best clinical prognostic tools available in metastatic breast cancer (Fig.
5).
4. Discussion
The confounding clinical reality is that cancer patients with similar
clinical diagnoses often exhibit diverse tumor responses and varied sur-
vival following standard-of-care therapies, emphasizing the clinical
need and intellectual challenges of personalizedmedicine in breast can-
cer (Tevaarwerk et al., 2013; Gyorffy et al., 2015; Zardavas et al., 2015;
Vogelstein et al., 2013). There is a pressing need to develop and incorpo-
rate reliable prognostic tools that can determine which invasive mam-
mary tumors are most likely to beneﬁt from the prescribed
neoadjuvant and adjuvant modalities, given intrinsic tumor heteroge-
neity and the emergence of resistant clones post systemic therapy
(Zardavas et al., 2013; King and Morrow, 2015; Hutchinson, 2010;
Coley, 2008; Holohan et al., 2013; Haddad and Goetz, 2015). Molecular
assessment tools can be combined with clinicopathological predictors
to identify unique tumor vulnerability, optimize therapies, forecast
tumor response, estimate risk of recurrence and predict survival, in-
clude Oncotype DX and MammaPrint (Gyorffy et al., 2015; Sparano et
al., 2015; Albain et al., 2010). Despite great promises, these multigene
prognostic tools require clinical reﬁnements to increase prognostic ac-
curacy (Gyorffy et al., 2015; Oakman et al., 2010; Goncalves and Bose,
2013). Therapy-responsive and growth-dependent biomarkers are
needed to identify which patients’ tumors are responding to the giventherapies, independent ofmammary tumor heterogeneity, so that effec-
tive therapy can be tailored and enhanced in response to the emergence
of resistant tumor clones in real time. Hence, new techniques are need-
ed to select the most effective ﬁrst-line therapies for breast cancer pa-
tients with metastatic diseases to extend their survival (Weigelt et al.,
2005; Yap et al., 2012; Gerlinger et al., 2012).
The administration of NST has become a standard therapy for breast
cancer patients with invasive, inﬂammatory and high-risk disease
(Swain et al., 2015; Zardavas et al., 2013; King and Morrow, 2015;
Tevaarwerk et al., 2013). NST reduces tumor burden before surgical re-
section, and it provides a valuable opportunity to assess therapy efﬁcacy
using pre-operative and post-operative tumor biospecimens (Graham
et al., 2014). Patients have achieved complete tumor remission based
on clinicopathological analysis post-NST, have increased disease-free
survival (Thompson and Moulder-Thompson, 2012; Morrow, 2016;
Schott and Hayes, 2012). Identifying patients as “super-responders”,
“partial responders” and “non-responders” using an improved panel of
logical, integrated and robust molecular biomarkers could help oncolo-
gists identify effective ﬁrst-line therapies for patientswith high-risk and
malignant breast cancer. Therapies for invasive and high-risk breast
cancer (luminal, basal-like, HER2-positive and TNBC) are often selected
based on tumor ER, PR and HER2 status as well as clinicopathological
predictors such as age, tumor size, stage, lymph node status, local inva-
sion and systemic metastasis (Baselga et al., 2012; Bevers et al., 2009;
Redden and Fuhrman, 2013; Tolaney et al., 2015). However, ER, PR,
and HER2 expression in high-grade, therapy-resistant, invasive and
metastatic mammary tumors does not correlate with progression-free
Fig. 3. SIAH and EGFR expression in node-negative and node-positive breast cancer pre- and post-NST. (A–B) The box-and-whisker plots were used to graphically illustrate the population
distribution of SIAH (A) and EGFR (B) expression levels in both node-positive (as marked by purple color bar graphs) and node-negative (as marked by teal color bar graphs) mammary
tumors. The SIAH/EGFR expression patterns in the 4molecular subtypes, Luminal A (LumA) or Luminal B (Lum B), HER2+ and TNBC, were shown pre- and post-NST treatment. The error
bars or whiskers in the histogram and bar charts represent the 95% CI, and in the box plots, they represent the upper (top) and lower quartiles (bottom) data distribution –with points
beyond representing outliers. (C–F). Serialmicro-sectionswere cut from each tumor parafﬁn blocks and the tissue slideswere stainedwith H&E, SIAH, EGFR or Ki67monoclonal antibody.
Representative images of SIAH, EGFR, Ki67 staining innode-negative super-responders (C), node-positive super-responders (D), and node-negative non-responders (E) andnode-positive
non-responders (F), were shown. SIAH marked proliferating tumor cells, independent of nodal status in breast cancer. Note the lack of SIAH expression in super-responders post-NST
correlated with good outcome, whereas persisted SIAH expression post-NST in non-responders correlated with poor survival.
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Fig. 4. Among patients with LN metastases, decreased SIAH expression post-NST and therapy-induced reduction in EGFR expression, are correlated with improved patient survival. Kaplan-Meier analysis was used to generate survival curves to
compare survival time among patients with and without LN metastases, whose tumors have high versus low SIAH/EGFR expression pre- and post-NST. Death occurred only in patients with LN metastases: all patients without sentinel LN
metastases survived for 7-years, independent of biomarker expression. (A) SIAH expression in treatment-naïve tumors did not correlate with survival. (B) SIAH expression post-NST statistically correlated with survival. (C) Therapy-induced
changes in SIAH expression did not correlate with survival. (D) EGFR expression in treatment-naïve tumors did not correlate with survival. (E) EGFR expression post-NST did not correlate with survival. (F) Therapy-induced changes in EGFR
statistically correlated with patient survival. Numbers of patients at risk are listed under each K-M curve.
193
L.L.S.van
Reesem
a
etal./EBioM
edicine
11
(2016)
183–198
Fig. 5.Multivariate analyses of six biomarkers, LNmetastases, and four clinicopathological predictors in predicting patient survival in breast cancer. (A–C)Area under curve (AUC) plots for
the ﬁrst 5-years based on SIAH, EGFR, Ki67 and/or ER/PR/HER2 expression, alone or in combination, are shown, pre-NST (A), post-NST (B), and NST-induced reduction of these six
biomarkers (C). The AUC plots include ER, PR and HER2 in combination (red line), Ki67 (neon green line), EGFR (orange line), SIAH (light teal line), SIAH and EGFR (blue line), SIAH,
EGFR and Ki67 in combination (black line). The data showed that SIAH and EGFR, alone or in combination, outperform ER, PR, HER2 and/or Ki67 in predicting patient survival. (D–F)
AUC plots for the ﬁrst 5-years based on SIAH and EGFR, ER/PR/HER2 expression, LN metastases and/or four clinicopathological predictors, alone or in combination, in pre-NST (D),
post-NST (E), and NST-induced reduction of these six biomarkers and four clinicopathological predictors (F). The AUC plots include ER, PR and HER2 in combination (red line), 4
clinicopathological predictors (neon green line), LN metastases (blue line), SIAH and EGFR in combination (black line). The data showed that the prognostic values of SIAH and EGFR,
alone or in combination, are comparable to the four clinicopathological predictors, in predicting survival. (G–I) The time-dependent survival ROC curves for the ﬁrst 5 years based on
SIAH, EGFR, Ki67 and/or ER/PR/HER2 expression, alone or in combination, are shown, in pre-NST (G), post-NST (H), and NST-induced reduction of these six biomarkers (I) in
predicting survival. The survival ROC curves include ER, PR and HER2 in combination (red line), Ki67 (neon green line), EGFR (orange line), SIAH (light teal line), SIAH and EGFR (blue
line), SIAH, EGFR and Ki67 in combination (black line). SIAH and EGFR, two RAS pathway biomarkers alone or in combination, outperform ER, PR, HER2 and Ki67 in predicting patient
survival. (J–L) Time-dependent survival ROC curves for the ﬁrst 5-years based on SIAH and EGFR, and/or ER/PR/HER2 in combination with LN metastases, and the four
clinicopathological predictors, alone or in combination, are shown, in pre-NST (J), post-NST settings (K), and NST-induced reduction of these six biomarkers (L). The survival ROC
curves include ER, PR and HER2 in combination (red line), SIAH and EGFR in combination (black line), LN metastases (blue line), and 4 clinical predictors together (neon green line).
The data showed that the prognostic values of SIAH and EGFR, alone or in combination, are comparable to the four clinicopathological predictors, in predicting survival in breast cancer.
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al., 2013; Gown, 2008; Chen et al., 2012; Onitilo et al., 2009; Parise
and Caggiano, 2014; Prat et al., 2015).
As a major tumor-promoting pathway, RAS pathway activation/in-
activation is ideally positioned to serve as a therapy-responsive, tumor
heterogeneity-independent, and growth-dependent prognostic bio-
marker in breast cancer. Here, we conducted a retrospective study to
determine whether the RAS pathway biomarkers can be added to eval-
uate tumor response and therapy efﬁcacy, forecast patient survival, and
predict which patients with invasive breast cancer are likely to beneﬁt
from standard NST regimens, or which patients will beneﬁt from addi-
tional regimens after ineffective ﬁrst-line therapies are identiﬁed.
SIAH function is required for proper HER2/EGFR/K-RAS signal transduc-
tion, cancer cell proliferation and survival (Schmidt et al., 2007; Ahmed
et al., 2008; Qin et al., 2015; Tang et al., 1997; Adam et al., 2015). SIAH is
expressed in proliferating tumor cells. We have previously associated
increased SIAH expression with the progression of ductal carcinoma in
situ (DCIS) to invasive carcinoma (Behling et al., 2010). We showed
that combining ﬁve molecular biomarkers (EGFR, SIAH, phospho-ERK,
Ki67 and HIF1α) in the oncogenic K-RAS/Ki67/HIF1α pathways, with
four clinicopathological predictors can be used to predict patient surviv-
al post surgery in human pancreatic cancer (Qin et al., 2015). Other
groups have shown that SIAH expressed in breast cancer (Wright et
al., 2015; Palmieri et al., 2009; Bruzzoni-Giovanelli et al., 2010;
Confalonieri et al., 2009; Chan et al., 2011). Importantly, we were the
ﬁrst group to demonstrate the efﬁcacy of an anti-SIAH-based anti-K-
RAS and anticancer strategy to shutdown the “undruggable” oncogenic
K-RAS activation and successfully block oncogenic K-RAS-driven tumor-
igenesis in several animalmodels of human cancer (Schmidt et al., 2007;
Ahmed et al., 2008; Van Sciver et al., 2016; Wong and Moller, 2013).
SIAH expression reﬂects RAS pathway activation, cell proliferation,
and tumor growth (Schmidt et al., 2007; Ahmed et al., 2008; Tang et
al., 1997). As a therapy-responsive and tumor heterogeneity-indepen-
dent RAS pathway biomarker, SIAH is uniquely positioned to identify
super-responders, partial-responders, and non-responders in the neo-
adjuvant setting to allow real-time monitoring, augmentation and
quantiﬁcation of therapy efﬁcacy, to improve clinical outcome and pa-
tient survival (Fig. 6, a schematic illustration). We found that SIAH is a
robust, tumor-speciﬁc and therapy-responsive tumor biomarker that
can be used to identify which patients are most likely to beneﬁt from
a given NST regimen as a ﬁrst-line therapy, and which patients should
receive additional augmented and combinational therapies in the case
of ineffective NST (Figs. 2, 3, 4 and 5). Independent of therapy-induced
tumor debulking, SIAH expression post-NST appears to have important
prognostic value to detect the emergence of resistant tumor clones, dif-
ferentiate among partial responders, forecast tumor relapse or remis-
sion, and predict survival in malignant breast cancer (Fig. 6).
Despite showing promising prognostic potential, there are several
limitations to consider when interpreting our results. It is retrospective
in design and included a limited number of 182 breast cancer patients.
Up to 7 years post initial diagnosis, survivalwas shortest among patients
whose tumors spread to the lymph nodes and beyond,whereas patients
with node-negativemammary tumors all survived for 7-years (Figs. 3, 4
and 5). A longer study (10–15 years) will be followed up to determine
the prognostic power of SIAH and EGFR in noninvasive mammary tu-
mors. Although the survival curves indicate that reduced levels of
SIAH and EGFR post-NST are good prognostic biomarkers that predict
effective treatment, and tumor remission (Figs. 2, 3, 4 and 5), the ulti-
mate clinical incorporation of SIAHand EGFR inmetastatic breast cancer
will require large-scale and independent validations at multiple NCI-
designated comprehensive cancer centers.
Our study identiﬁed that roughly 20% of locally advanced andmeta-
static mammary tumors have upregulated EGFR, and that EGFR expres-
sion levels decrease post-NST (Figs. 1 and 3, and Table 1). EGFR
expression is associated with aggressive molecular subtypes such as
TNBC subtype independent of LN status, and HER2+ subtype with LNmetastases. PostNST treatment, EGFR expression persisted in TNBC sub-
type independent of LN status, suggesting that anti-EGFR therapy is
likely to offer additional therapeutic beneﬁts to the patients with thera-
py-refractory and EGFR-positive TNBC tumors (Fig. 3B). Our ﬁndings
may be important because they indicate that FDA-approved anti-EGFR
therapeutics should be added to treat TNBC patients whose tumors
are therapy-refractory and EGFR-positive. By comparing the percentage
reduction in SIAH or EGFR expression pre- and post-NST,wewill be able
to identify and quantify super-, partial- and non-responders among
breast cancer patients who received standard therapies. Successful val-
idation of the prognosis of these RAS pathway biomarkers among “par-
tial responders” with invasive breast cancer may have clear clinical
impact (Fig. 6). As a control, Ki67 has shown limited or contradictory
prognostic values (Loehberg et al., 2013). SIAH seems to be a better,
more sensitive and therapy-responsive biomarker than Ki67 in breast
cancer (Figs. 1 and 5, and Supplemental Fig. S1). The prognostic value
of SIAH and EGFR expression in locally advanced and metastatic breast
cancer is superior and/or comparable to LN status and established clin-
icopathological predictors (AUC and ROC curves, Fig. 5). This SIAH/
EGFR-centered biomarker panel may be used to determine tumor re-
sponse to NST, tailor and optimize NST, and improve patient survival
in the future. Importantly, our results show that therapy-induced reduc-
tion in SIAH and/or EGFR expression reﬂects RAS pathway activation/in-
activation, and outperforms ER, PR, HER2 and Ki67 as a promising and
prognostic biomarker in invasive and metastatic breast cancer. SIAH is
expressed in 97.8% treatment-naïve breast cancer whereas EGFR is
expressed in 20% of untreated population. Thus, the prognostic value
of SIAH outperforms EGFR in malignant breast cancer (Figs. 2, 3, 4 and
5). Conceptually, SIAH and EGFR offer an accurate readout of therapeu-
tic efﬁcacy independent of tumor heterogeneity, thus providing a valu-
able window of opportunity to quantify tumor responses, to reduce
drug toxicity and to improve therapy efﬁcacy against invasive breast
cancer in real time. A prospective study will be performed to validate
the prognostic value and therapy-responsiveness of SIAH and EGFR, to
forecast and monitor therapy-induced tumor regression, estimate NST
efﬁcacy, differentiate the “partial responders” and identify therapy-in-
duced resistant clonal expansion, and to ultimately improve patient sur-
vival in the future.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.08.014.
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